Anzeige
Erschienen in:
01.08.2019 | Sleep Breathing Physiology and Disorders • Original Article
Circulating adipocyte fatty acid–binding protein is reduced by continuous positive airway pressure treatment for obstructive sleep apnea—a randomized controlled study
Erschienen in: Sleep and Breathing | Ausgabe 3/2020
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The circulating level of adipocyte fatty acid–binding protein (AFABP), a biomarker with prognostic and therapeutic importance in metabolic disorders, has been shown to be elevated in obstructive sleep apnea (OSA). This randomized controlled study aimed to investigate the effect of continuous positive airway pressure (CPAP) treatment for OSA on AFABP levels.
Methods
Consecutive subjects attending sleep study were invited if they were confirmed to have severe OSA and were free of metabolic diseases. Participants were randomized (1:1) into CPAP or observation group for 4 weeks. Demographics, anthropometric data, and circulating biomarkers were checked at baseline and after the 4-week study period.
Results
Ninety subjects were randomized. The mean age was 46 ± 9 years old; 82% were male. Their mean body mass index (BMI) was 29 ± 5 kg/m2. By intention-to-treat approach, the CPAP group showed significant reductions in Epworth sleepiness scale and morning systolic blood pressure (− 7.2 mmHg, − 12.7 to − 1.7 mmHg, p = 0.011), but no significant difference in AFABP, adiponectin, C-reactive protein (CRP), and 8-isoprostane levels. In the per-protocol analysis, when only those who were compliant to CPAP were included, a significant reduction in AFABP (− 7.32 ng/ml, − 13.58, − 1.06, p = 0.023) were found in the CPAP-treated group compared with the control group, along with improvements in clinical parameters. Changes in AFABP were independently associated with both systolic blood pressure (β = 0.289, p = 0.028) and diastolic blood pressure (β = 0.217, p = 0.030).
Conclusion
CPAP therapy used regularly over 4 weeks for severe OSA lowered circulating AFABP level, suggesting a potential beneficial effect of OSA treatment on alleviating metabolic risks.
Trial registration
The research protocol was registered at the National Institutes of Health clinical trials registry (NCT01173432).